

MAGNIFY

the art & science of diagnostic medicine

ARUP Laboratories Leads Industry in Both Drug Testing and Cytogenetics

In the latest issue of Magnify: The Art and Science of Diagnostic Medicine, we explore ARUP's innovative approaches to drug testing and commitment to cytogenetics testing, and we highlight the medical directors who lead advancements in these testing areas. Read and share the stories at aruplab.com/magnify-fall23.



Phenotype variance



Variable drug metabolism and response



Variable drug effect



ARUP Continues to Pioneer Improved Drug Testing to Support Patient Care

ARUP's Clinical Toxicology and Pharmacogenomics team members share a determination to drive change that leads to better patient outcomes and yields quality results for tens of thousands of patients each month.

► aruplab.com/magnify-fall23-drug



Visionary Clinical Toxicologist Gwen McMillin Has Transformed Drug Testing to Better Support Clinical Needs

Gwen McMillin, PhD, DABCC (CC, TC), FAACC, has applied her unique vision and perspective to transform the field of clinical toxicology and has propelled drug testing to become more relevant and efficient.

► aruplab.com/magnify-fall23-mcmillin



ARUP Takes a Forward-Thinking Approach to Newborn Drug Screening

A focus on quick, accurate, qualitative test results to inform time-sensitive decision-making keeps ARUP at the forefront of newborn drug screening.

► aruplab.com/magnify-fall23-newborn



Answers Patients Can Trust: ARUP Expands Capacity for Cytogenetics Testing, Offering a Full Test Menu, Access to Related Tests, and Broad Testing Expertise

As other labs have discontinued cytogenetics testing, ARUP has committed to this highly specialized testing for the long term, investing in instruments and space and continuing to build expertise with a goal to increase testing volumes by 20% a year.

► aruplab.com/magnify-fall23-cytogenetics